Presentation is loading. Please wait.

Presentation is loading. Please wait.

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,

Published byGauthier Marin Modified over 6 years ago

Similar presentations

Presentation on theme: "A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,"— Presentation transcript:

1 A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau, Jeffrey E. Lancet, Josy Reiffers, Bob Lowenberg, Xavier Thomas, Francoise Huguet, Pierre Fenaux, Steven Zhang, Wayne Rackoff, Peter De Porre, and Richard Stone Blood Volume 109(12): June 15, 2007 ©2007 by American Society of Hematology

2 Mean (± SD) tipifarnib concentration vs time profile after 600 mg oral administration (n = 17).
Jean-Luc Harousseau et al. Blood 2007;109: ©2007 by American Society of Hematology

3 Overall survival. Overall survival. Kaplan-Meier estimate of the overall population survival (n = 252). The median survival was 87 days (95% confidence interval [CI], days). Estimated survival rate of 26% at 6 months and 12% at 12 months. Jean-Luc Harousseau et al. Blood 2007;109: ©2007 by American Society of Hematology

4 Overall survival according to response.
Overall survival according to response. Kaplan-Meier estimate of overall survival as a function of response. Jean-Luc Harousseau et al. Blood 2007;109: ©2007 by American Society of Hematology

Download ppt "A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,"

Similar presentations

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,
Combination therapy for adult T-cell leukemia–xenografted mice: flavopiridol and anti-CD25 monoclonal antibody by Meili Zhang, Zhuo Zhang, Carolyn K. Goldman,

Combination therapy for adult T-cell leukemia–xenografted mice: flavopiridol and anti-CD25 monoclonal antibody by Meili Zhang, Zhuo Zhang, Carolyn K. Goldman,
Long-Term Follow-Up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia:

Long-Term Follow-Up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia:
Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,
Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,
Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup by Jacques Delaunay, Norbert Vey, Thierry.

Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup by Jacques Delaunay, Norbert Vey, Thierry.
Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen.

Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen.
Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup by Marie-Anne Hospital, Thomas Prebet,

Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup by Marie-Anne Hospital, Thomas Prebet,
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,
Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic.

Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic.
Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic.

Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic.
Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy by Kendra L. Sweet, Najla H Al Ali, Jeffrey.

Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy by Kendra L. Sweet, Najla H Al Ali, Jeffrey.
Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study by Yu Wang, Qi-Fa Liu, Lan-Ping Xu, Kai-Yan Liu,

Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study by Yu Wang, Qi-Fa Liu, Lan-Ping Xu, Kai-Yan Liu,
by Sandra Luna-Fineman, Kevin M. Shannon, Susan K

by Sandra Luna-Fineman, Kevin M. Shannon, Susan K
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion.

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion.
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value by Saman.

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value by Saman.
NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on.

NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on.
by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu

by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu
Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia by Yves Chalandon, Xavier.

Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia by Yves Chalandon, Xavier.

Similar presentations

Ads by Google